HepaRG-AMC
Liver transplantation
bioartificial liver
HepaRG-Bio
human liver cell line HepaRG
severe liver failure
feasibility plan
GMP-compliant production of HepaRG
AMC-BALs
expansion of business plan End-stage liver disease patients
dramatic loss of functional liver tissue
cell expansion
BALXPAND project
resulting updated business plan
Feasibility of commercialization
effective therapy
list of large medical device companies
realistic estimation of production costs
prerequisite
Contract Manufacturing Organisations
future corporate partners
stabilization
phase
trials
animals
bioreactor
new data
survival time
number of pilot
possible recovery
economic perspective
functionality
commercialisation
SME Hep-Art
patient's circulation
shortage of donor livers
system
safety
life
consequence
mortality